Interestingly, the engagement of endocytic receptors favors Ag presenting pDC functions, while it dampens their ability to produce IFN-I, suggesting that Ag targeting in pDCs would represent an attractive therapeutical strategy to control autoimmunity and graft rejection. Here, RENBP is linked to Autoimmunity.